Table 2.
The association between THRα1 expression and clinicopathological characteristics of NSCLC (SCC) cases (No = 48).
| Clinicopathological characteristics | THRα expression | p value | ||
|---|---|---|---|---|
| Low (%) | Intermediate (%) | High (%) | ||
| Age | ||||
| ≤ 55 | 2 (16.7) | 4 (33.3) | 6 (50) | 0.232 |
| > 55 | 2 (5.6) | 8 (22.2) | 26 (72.2) | |
| Gender | ||||
| Male | 4 (10.5) | 9 (23.7) | 25 (65.8) | 0.742 |
| Female | 0 (0) | 3 (30) | 7 (70) | |
| Tumor grade | ||||
| GI | 3 (50) | 0 (0) | 3 (50) | 0.011* |
| GII | 1 (4.3) | 8 (34.8) | 14 (60.9) | |
| GIII | 0 (0) | 4 (21.1) | 15 (78.9) | |
| T stage | ||||
| T1 | 2 (50) | 0 (0) | 2 (50) | 0.001* |
| T2 | 2 (6.7) | 12 (40) | 16 (53.3) | |
| T3 | 0 (0) | 0 (0) | 14 (100) | |
| N stage | ||||
| N0 | 2 (9.5) | 9 (42.9) | 10 (47.6) | 0.007* |
| N1 | 2 (15.4) | 3 (23.1) | 8 (61.5) | |
| N2 | 0 (0) | 0 (0) | 14 (100) | |
| Metastasis | ||||
| M0 | 4 (10.8) | 12 (32.4) | 21 (56.8) | 0.017* |
| M1 | 0 (0) | 0 (0) | 11 (100) | |
| TNM stage | ||||
| Stage I | 2 (13.3) | 8 (53.3) | 5 (33.3) | 0.003* |
| Stage II | 2 (13.3) | 4 (26.7) | 9 (60) | |
| Stage III | 0 (0) | 0 (0) | 7 (100) | |
| Stage IV | 0 (0) | 0 (0) | 11 (100) | |
| Overall survival | ||||
| Censored | 3 (23.1) | 6 (46.2) | 4 (30.8) | 0.003* |
| Event | 1 (2.9) | 6 (17.1) | 28 (80) | |
Test of significance: Chi-square and Fisher exact tests.
p-value < 0.05 is considered significant.